Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy

Medical Hypotheses

Volumn 76, Issue 5, 2011, Pages 695-696

  Wang, Jiansheng ^a   Zhang, Jia ^a   Sun, Junping ^b   Han, Jiangli ^c   Xi, Yutao ^b   Wu, Geru ^b   Duan, Kristina X ^b   Zhang, Mingxin ^a   Zhou, Suna ^a   Liu, Qi ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ILOPROST; PROSTACYCLIN; PROSTACYCLIN SYNTHASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY;

ANGIOGRAPHY; ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DOXORUBICIN; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; ILOPROST; MICE; MYOCYTES, CARDIAC; NEOPLASMS; OXIDATIVE STRESS; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 79954424592     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.01.036     Document Type: Article

References (32)

1. Bunting S., Gryglewski R., Moncada S., Vane J.R. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 1976, 12:897-913.
2. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002, 68-69:165-175.
3. Hinz B., Brune K. Cyclooxygenase-2-10years later. J Pharmacol Exp Ther 2002, 300:367-375.
4. Smith E.F., Gallenkamper W., Beckmann R., Thomsen T., Mannesmann G., et al. Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 1984, 18:163-173.
5. Schror K., Woditsch I. Endogenous prostacyclin preserves myocardial function and endothelium-derived nitric oxide formation in myocardial ischemia. Agents Actions Suppl 1992, 37:312-319.
6. Woditsch I., Schror K. Prostacyclin rather than endogenous nitric oxide is a tissue protective factor in myocardial ischemia. Am J Physiol 1992, 263:H1390-1396.
7. Szekeres L., Koltai M., Pataricza J., Takats I., Udvary E. On the late antiischaemic action of the stable PgI2 analogue: 7-oxo-PgI2-Na and its possible mode of action. Biomed Biochim Acta 1984, 43:S135-142.
8. Darius H., Osborne J.A., Reibel D.K., Lefer A.M. Protective actions of a stable prostacyclin analog in ischemia induced membrane damage in rat myocardium. J Mol Cell Cardiol 1987, 19:243-250.
9. Penna C., Mancardi D., Tullio F., Pagliaro P. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 2008, 103:368-377.
10. Ueno Y., Shigenobu K., Nishio S. Effect of beraprost sodium on changes in action potentials during hypoxia as compared with propranolol, diltiazem and glibenclamide in guinea-pig ventricular muscle. Arch Int Pharmacodyn Ther 1994, 328:191-199.
11. Tanaka H., Matsui S., Shigenobu K. Cardioprotective effects of beraprost sodium against experimental ischemia and reperfusion as compared with propranolol and diltiazem. Res Commun Mol Pathol Pharmacol 1998, 99:321-327.
12. Shinmura K., Tamaki K., Sato T., Ishida H., Bolli R. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. Am J Physiol Heart Circ Physiol 2005, 288:H2093-2101.
13. Libby P., Warner S.J., Friedman G.B. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988, 81:487-498.
14. Hubbard W.C., Alley M.C., Gray G.N., Green K.C., McLemore T.L., Boyd M.R. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res 1989, 49:826-832.
15. McLemore T.L., Hubbard W.C., Litterst C.L., Liu M.C., Miller S., McMahon N.A., et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 1988, 48:3140-3147.
16. Kreutzer M., Fauti T., Kaddatz K., Seifart C., Neubauer A., Schweer H., et al. Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells. Oncol Rep 2007, 18:497-501.
17. Pradono P., Tazawa R., Maemondo M., Tanaka M., Usui K., Saijo Y., et al. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 2002, 62:63-66.
18. Keith R.L., Miller Y.E., Hoshikawa Y., Moore M.D., Gesell T.L., Gao B., et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002, 62:734-740.
19. Keith R.L., Miller Y.E., Hudish T.M., Girod C.E., Sotto-Santiago S., Franklin W.A., et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 2004, 64:5897-5904.
20. Cuneo K.C., Fu A., Osusky K.L., Geng L. Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anticancer Drugs 2007, 18:349-355.
21. Nemenoff R., Meyer A.M., Hudish T.M., Mozer A.B., Snee A., Narumiya S., et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev Res (Phila) 2008, 1:349-356.
22. Tennis M.A., Van Scoyk M., Heasley L.E., Vandervest K., Weiser-Evans M., Freeman S., et al. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia 2010, 12:244-253.
23. Li E.C., Esterly J.S., Pohl S., Scott S.D., McBride B.F. Drug-induced QT-interval prolongation: considerations for clinicians. Pharmacotherapy 2010, 30:684-701.
24. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14-25.
25. Curigliano G., Mayer E.L., Burstein H.J., Winer E.P., Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 2010, 53:94-104.
26. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010, 7:564-575.
27. Minami M., Matsumoto S., Horiuchi H. Cardiovascular side-effects of modern cancer therapy. Circ J 2010, 74:1779-1786.
28. Monsuez J.J., Charniot J.C., Vignat N., Artigou J.Y. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010, 144:3-15.
29. Raschi E., Vasina V., Ursino M.G., Boriani G., Martoni A., De Ponti F. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010, 125:196-218.
30. Dowd N.P., Scully M., Adderley S.R., Cunningham A.J., Fitzgerald D.J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001, 108:585-590.
31. Neilan T.G., Jassal D.S., Scully M.F., Chen G., Deflandre C., McAllister H., et al. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J 2006, 27:1251-1256.
32. Neilan T.G., Doherty G.A., Chen G., Deflandre C., McAllister H., Butler R.K., et al. Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. Am J Physiol Heart Circ Physiol 2006, 291:H532-536.